Weight-Loss drug semaglutide takes on PCOS in teen girls

NCT ID NCT03919929

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study tested whether the diabetes drug semaglutide (Rybelsus) could help 60 adolescent girls with PCOS and obesity reduce liver fat and improve insulin sensitivity, compared to a weight loss diet. Participants took a daily oral tablet for 4 months or followed a prescribed diet. The goal was to see if the drug could better manage metabolic syndrome linked to PCOS.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
semaglutide (Rybelsus)
What this could lead to
If it works, this could point toward a medication option for managing PCOS-related metabolic issues in teens without lifelong hormone therapy.
What could go wrong
This is a small, early-phase study with only 60 participants, so results may not apply broadly. Semaglutide can cause nausea and other side effects, and the diet group may not achieve similar weight loss.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADOLESCENT OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Colorado Anshutz Medical Campus/Children's Hospital Colorado

    Aurora, Colorado, 80045, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.